Category: Clinical Pharmacology & Modeling
Aclairo Welcomes Dr. Heath Thomas as New President
Experimental Pathology Laboratories, Inc. (EPL) and Aclairo Pharmaceutical Development Group, Inc. (Aclairo) are excited to announce that Dr. Heath Thomas has joined Aclairo as President and Senior Consultant. Dr. Thomas is a board-certified veterinary pathologist with over 20 years of experience in drug development from time spent with SmithKline Beecham, DuPont Pharmaceuticals, and GlaxoSmithKline, as […]
Use of Exposure-Response (ER) Modeling of QTc Data – A Movement Away from a Thorough QT Study
Since 2005 the US Food and Drug Administration (FDA) has required the evaluation of a new molecular entity in a thorough QT (TQT) study, which is intended to determine a drug’s effect on the QT interval. The QT interval represents the duration of ventricular depolarization and subsequent cardiac repolarization, measured from the beginning of the […]
Get to Know Aclairo
Aclairo® Pharmaceutical Development Group, Inc. is committed to delivering independent and objective nonclinical and regulatory advice to the pharmaceutical industry. Every member of Aclairo’s staff strives to provide our clients with superior advice, analysis, work product and program assistance. Aclairo’s unique experience and capabilities help our clients’ development programs succeed. Our senior consultants are experienced ex-FDA […]
Meet Aclairo Pharmaceutical Development Group
Imagine a group of great scientists and all around nice folks who worked with another group for years in dovetailed projects for their clients. It does not take much imagination to wonder why these folks would want to be in one happy group together. On January 1, 2016, EPL, Inc. acquired Aclairo PDG, Inc. as […]
Experimental Pathology Laboratories, Inc. (EPL) Acquires Aclairo Pharmaceutical Development Group, Inc.
EPL and Aclairo Combine Preclinical Services Expertise EPL is pleased to announce that it has acquired Aclairo Pharmaceutical Development Group, Inc. (Aclairo) which provides independent and objective nonclinical, regulatory, and clinical ADME/DMPK expert strategy and implementation to the pharmaceutical and drug device industries. “Aclairo’s team of industry and ex-FDA experts have developed a specialized consultancy […]